Oxidative Medicine and Cellular Longevity / 2020 / Article / Fig 3

Research Article

Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways

Figure 3

Trastuzumab plus brusatol potently inhibited the activation of Nrf2/HO-1 and HER2-AKT/ERK1/2 pathways. (a, b) BT-474 and SK-OV-3 cells were treated with trastuzumab or brusatol alone, or their combination for 24 hours. The changes in Nrf2/HO-1 and HER2-AKT/ERK1/2 signaling pathways were monitored by western blotting. (c, d) Densitometric analysis was performed on the western blotting. The levels of Nrf2, HO-1, p-HER2, p-AKT, and p-ERK1/2 were quantified by using the software Image J. The data are expressed as the of three independent experiments. , , .
(a)
(b)
(c)
(d)

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.